VHPB Centre for Evaluation of Vaccination (CEV) |
Executive Secretary Administrative and Scientific Secretariat |
privacy statement
|
Edinburgh, United Kingdom, November 17-18, 2005
Thursday, November 17, 2005
Session 1 Opening and objectives
Chair: Claire Cameron and Mark Kane
09.00 - 09.20
Session 2 Scene setting
Chair: Claire Cameron and Mark Kane
09.20 - 10.15
How England, Wales, Scotland, and Northern Ireland fit together – politics, healthcare, decision making, research, funding 129 Kb (.pdf)
Howard Thomas, London, UK
10.15 - 10.30
Coffee break
Session 3 Hepatitis B: selective vaccination or selective plus universal vaccination
Chair: David Goldberg and André Meheus
10.30 – 11.00
Epidemiology of hepatitis B in the UK 680 Kb (.pdf)
Mary Ramsay, London, UK
11.00 - 11.30
Virology of hepatitis B 1150 Kb (.pdf)
William Carman, Glasgow, UK
11.30 – 12.00
Clinical aspects 324 Kb (.pdf)
Geoffrey Dusheiko, London, UK
12.00 - 13.30
Lunch
13.30 – 14.00
Hepatitis B: public health aspects – Glasgow 208 Kb (.pdf)
Syed Ahmed, Glasgow, UK
14.00 - 14.30
Hepatitis B: public health aspects – London 1074 Kb (.pdf)
Helen Maguire, London, UK
14.30 – 15.00
Hepatitis B: economic aspects 211 Kb (.pdf)
John Edmunds, London, UK
15.00 - 15.15
Coffee break
Session 4 Hepatitis C
Chair: Howard Thomas and Daniel Lavanchy
15.15 - 15.45
Epidemiology of hepatitis C in the UK 556 Kb (.pdf)
Kirsty Roy, Glasgow, UK
15.45 - 16.15
The cost effectiveness of case-finding strategies for HCV infection in former injecting drug users 148 Kb (.pdf)
Ken Stein, Exeter, UK
16.15 - 16.45
Management of diagnosed cases of hepatitis C virus infection 534 Kb (.pdf)
Mark Thursz, London, UK
16.45 - 17.15
National hepatitis C strategy / Action plans / SIGN guidelines 492 Kb (.pdf)
John Dillon, UK
Friday, November 18, 2005
Session 4 Hepatitis C (Continued)
Chair: Mary Ramsay and Daniel Shouval
09.00 - 09.30
Hepatitis C virus infection: monitoring of end-stage liver disease and modelling the current and future burden of disease 564 Kb (.pdf)
Sharon Hutchinson, Glasgow, UK
09.30 – 10.00
Modelling transmission of HCV among intravenous drug users and in prisons 174 Kb (.pdf)
Matthew Hickman, London, UK
10.00 - 10.30
Hepatitis C: economic issues 85 Kb (.pdf)
Richard Grieve, London, UK
10.30 - 11.00
Coffee break
Session 5 Hepatitis A
Chair: Mary Ramsay and Daniel Shouval
11.00 - 11.55
Epidemiology and control of hepatitis A in the UK 329 Kb (.pdf)
Natasha Crowcroft, London, UK
11.55 - 13.45
Lunch
Session 6 Conclusions of the meeting
Chair: William Carman and Steven Wiersma
13.45 - 14.45
VHPB preliminary meeting conclusions 50 Kb (.pdf)
Guido François
14.45
Close of the meeting